Verition Fund Management
CATX icon

Verition Fund Management’s Perspective Therapeutics CATX Stock Holding History

Verition Fund Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-115,255
Closed -$245K – 3649
2025
Q1 		$245K Sell
115,255
-10,435
-8% -$31.3K ﹤0.01% 2960
2024
Q4 		$401K Buy
125,690
+96,967
+338% +$792K ﹤0.01% 2610
2024
Q3 		$383K Buy
+28,723
New +$382K ﹤0.01% 2489

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Verition Fund Management's CATX Position: Q2 2025 in Review

Verition Fund Management sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 115,255 shares — an estimated $245K sold.

Verition Fund Management first reported a position in CATX in Q3 2024 and held it in 3 quarters. The position peaked at $401K in Q4 2024. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

  • Verition Fund Management reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 115,255 Perspective Therapeutics shares in Q2 2025, an estimated $245K.
  • Verition Fund Management first reported a position in Perspective Therapeutics in Q3 2024 and held it in 3 quarters.
  • Verition Fund Management's Perspective Therapeutics position peaked at $401K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.